Trial Profile
A study of PHC-102 for the imaging of renal cell carcinoma and other CAIX-expressing tumours
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 04 Mar 2017
Price :
$35
*
At a glance
- Drugs PHC 102 (Primary)
- Indications Prostate cancer; Renal cell carcinoma; Solid tumours
- Focus Diagnostic use
- 04 Mar 2017 New trial record